Brandon Capital Partners

Brandon Capital Partners investment thesis

Advancell Clinical-stage radiopharmaceutical company developing targeted alpha therapies to treat a broad range of cancers. Aravax Pty Ltd Developing peptide-based immunotherapies for food allergy treatment AstronauTx Cutting-edge biotech company founded to target neurodegenerative diseases by improving disrupted physiological processes leading to dementia. Axelia Oncology Biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response. Azura Ophthalmics Developing first-in-class ophthalmic keratolytics the first Pharmaceutical for the Treatment of Meibomian Gland Dysfunction CatalYm Reversing GDF-15-mediated immunosupression to induce anti-tumour responses Certa Therapeutics Certa Ther

Brandon Capital Partners team (24)

Partners and principals at Brandon Capital Partners:

• Rana Ali — sweet spot $1.5M
• Michael Bettess — sweet spot $1.5M
• Nadine Brew — sweet spot $1.5M
• Melissa Byrne — sweet spot $1.5M
• Julie Cherrington — sweet spot $1.5M
• Robert Daniels — sweet spot $1.5M
• Elliott Dunn — sweet spot $1.5M
• Katharine Giles — sweet spot $1.5M
• Jess Gledhill — sweet spot $1.5M
• Katherine Jackman — sweet spot $1.5M
• Christina Kulis — sweet spot $1.5M
• Mara Macdonald — sweet spot $1.5M
• Duncan Mackintosh — sweet spot $1.5M
• Melissa McBurnie — sweet spot $1.5M
• Tom McCarthy — sweet spot $1.5M
• Helga Mikkelsen — sweet spot $1.5M
• Chris Nave — sweet spot $1.5M
• Prashanth Rajan — sweet spot $1.5M
• Goslik Schepers — sweet spot $1.5M
• Christopher Smith — sweet spot $1.5M
• Bob Soh — sweet spot $1.5M
• Stephen Thompson — sweet spot $1.5M
• Jonathan Tobin — sweet spot $1.5M
• Ingmar Wahlqvist — sweet spot $1.5M

Brandon Capital Partners portfolio companies

Companies listed on Brandon Capital Partners's public materials include: About, Team, Investment Portfolio, Responsible Investing, News, Perspectives, Brandon BioCatalyst, Show all, Cardiovascular, Digital, Inflammation, Medical Devices, Neuroscience, Ocular, Oncology, Platform/Diagnostics, Vaccines, Clinical, Discovery, Exited, On Market, Pre-clinical, Elastagen, Ena Respiratory, Fibrotech Therapeutics, George Medicines, Longas, Mirugen, MycRx, Myricx Bio, NRG Therapeutics, OncoRes Medical, Pathios Therapeutics, Perx, Pheon Therapeutics, PKG Health (Global Kinetics), PolyActiva, Q-Sera, Respirion, Spinifex, Vaxxas, Certa Therapeutics, Cincera Therapeutics, EBR Systems, AstronauTx, Azura Ophthalmics, Advancell, Axelia, CatalYm, Currus Biologics, Aravax, Denteric, +61 3 9657 0700, Email: info@brandoncapital.com.au, +61 2 8227 7080, rheenan@bcpvc.com, +61 416 565 332.

Is Brandon Capital Partners a fit for your round?

Upload your pitch deck and see whether anyone at Brandon Capital Partners appears in your top matches.